Bristol Myers taps startup to boost CAR-T production
Bio Pharma Dive
APRIL 22, 2024
A partnership with Cellares, worth up to $380 million, is meant to help Bristol Myers speed and scale manufacture of the complex cellular treatments.
Mon.Apr 22, 2024
311 
Health Canada approves Merck’s KEYTRUDA for gastric cancer treatment
Pharmaceutical Technology
APRIL 22, 2024
Health Canada has approved Merck’s KEYTRUDA (pembrolizumab), an anti-programmed cell death protein 1 (PD-1) therapy for use in combination with fluoropyrimidine- and platinum-containing-chemotherapy as a first-line treatment for adult gastric cancer patients.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Eisai hunts for next Alzheimer’s drug with new research pact
Bio Pharma Dive
APRIL 22, 2024
A collaboration with BioArctic will focus on a technology designed to more effectively deliver drugs in the brain, following similar efforts by Roche.
Avidity Biosciences gets grant for polynucleic acid conjugate for treating FSHD through rna interference
Pharmaceutical Technology
APRIL 22, 2024
Discover how Avidity Biosciences' patented polynucleic acid molecule conjugate targets the DUX4 gene to combat FSHD. Learn more about this groundbreaking approach in gene therapy.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Lilly to buy injectable drug plant in manufacturing ramp-up
Bio Pharma Dive
APRIL 22, 2024
The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes and obesity.
BioMarin Pharmaceutical gets grant for treatment of adolescent PKU patients using AVPAL variant
Pharmaceutical Technology
APRIL 22, 2024
Discover how BioMarin Pharmaceutical's patent for PAL variants offers a groundbreaking method to treat PKU in adolescents. Administering AvPAL variants weekly over 50 weeks effectively reduces blood phenylalanine levels.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Datopotamab deruxtecan by Daiichi Sankyo for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Pharmaceutical Technology
APRIL 22, 2024
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).
Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
Bio Pharma Dive
APRIL 22, 2024
The deal, which could be worth up to $1.8 billion, is the latest research collaboration involving small molecule drugs that modify RNA.
Datopotamab deruxtecan by Daiichi Sankyo for Epithelial Ovarian Cancer: Likelihood of Approval
Pharmaceutical Technology
APRIL 22, 2024
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Epithelial Ovarian Cancer.
How can pharma speed time to treatment? Digital tools can help
Bio Pharma Dive
APRIL 22, 2024
Treatment delays can seriously impact patients’ health outcomes. But by leveraging digital tools, pharma can help them find and access specialist care early in their journey.
Datopotamab deruxtecan by Daiichi Sankyo for Metastatic Ovarian Cancer: Likelihood of Approval
Pharmaceutical Technology
APRIL 22, 2024
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Ovarian Cancer.
New NIHR HRC launched for cardiovascular and respiratory medicine
Pharma Times
APRIL 22, 2024
The launch is part of the NIHRs £42m funding to establish 14 new HRCs across England
Farletuzumab ecteribulin by Eisai for Ovarian Cancer: Likelihood of Approval
Pharmaceutical Technology
APRIL 22, 2024
Farletuzumab ecteribulin is under clinical development by Eisai and currently in Phase II for Ovarian Cancer.
What pharma stands to gain from technological innovation
pharmaphorum
APRIL 22, 2024
Pharmaceutical companies stand to gain significant benefits from technological innovation in the form of improved data analytics, streamlined healthcare processes, and enhanced patient outcomes. Explore the potential advantages for the pharma industry.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Chiesi champions new inhaler propellant to reduce carbon footprint
Pharmaceutical Technology
APRIL 22, 2024
Chiesi also purchased carbon credits to compensate for the emissions for its entire UK portfolio of respiratory medicines.
Study links dementia antipsychotics to higher risks of serious health outcomes
Pharma Times
APRIL 22, 2024
The neurodegenerative condition currently affects more than 944,000 people living in the UK
Spurred by rise in deals, experts say ADC innovation is set to advance
Pharmaceutical Technology
APRIL 22, 2024
At the Swiss Biotech Day conference, experts discussed how the development of antibody drug conjugates (ADCs) may evolve in the near future.
Earth Day 2024: How Webinars Shape Eco-Friendly Business Practices
XTalks
APRIL 22, 2024
Earth Day 2024 is an important rallying point for individuals, communities and organizations committed to environmental stewardship and sustainability. Initiated in 1970 and marked annually on April 22, Earth Day has grown into a global movement to highlight urgent actions that can help address environmental issues. Earth Day 2024 is an ideal platform for showcasing advancements and fostering collaborations that drive further innovation in facilitating a sustainable environment.
Hyundai to advance cancer study plans for niclosamide-based drug
Pharmaceutical Technology
APRIL 22, 2024
The niclosamide-based candidate has been repurposed as a cancer treatment by Hyundai and CNPharm after being originally developed for Covid-19.
US Supreme Court rejects Vanda's bid to revive patents on sleep disorder drug Hetlioz
Fierce Pharma
APRIL 22, 2024
The prospects for Vanda Pharmaceuticals’ 10-year-old circadian rhythm drug Hetlioz have grown that much dimmer after the U.S. | The prospects for Vanda Pharmaceuticals’ 10-year-old circadian rhythm drug Hetlioz have grown that much dimmer after the U.S. Supreme Court shot down the company’s attempt to challenge an appeals court decision invalidating several of the drug’s patents in 2023.
Tymlos outperforms teriparatide in real-world fracture analysis
Pharmaceutical Technology
APRIL 22, 2024
Radius Pharmaceuticals presented real-world evidence at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases on 12 April 2024, demonstrating that Tymlos therapy resulted in a lower incidence of hip and nonvertebral fractures compared to teriparatide therapy in women with osteoporosis aged 50 and older.
Ipsen signs $1.8bn RNA drug alliance with Skyhawk
pharmaphorum
APRIL 22, 2024
Ipsen agrees $1.8 bn alliance with Skyhawk Therapeutics focused on RNA-modulating drugs for rare neurological diseases.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Purdue Pharma gets grant for treatment of T-cell prolymphocytic leukemia using tinostamustine
Pharmaceutical Technology
APRIL 22, 2024
Discover the groundbreaking patent by Purdue Pharma for treating T-cell prolymphocytic leukemia with tinostamustine. Learn about the innovative kit and dosage guidelines for effective T-PLL treatment.
FDA Rejects Abeona’s Epidermolysis Bullosa Cell Therapy, Asks for CMC Data
BioSpace
APRIL 22, 2024
The regulator on Monday slapped Abeona Therapeutics with a Complete Response Letter for its investigational cell therapy pz-cel due to chemistry, manufacturing and controls issues.
Teladoc Health gets grant for contextual video searching method for telepresence devices
Pharmaceutical Technology
APRIL 22, 2024
Discover how Teladoc Health Inc's patent revolutionizes video search with a telepresence device, efficiently retrieving relevant segments based on situational data. Improve user experience and streamline access to pertinent information with this innovative technology.
AI in Drug Discovery: Day Two
pharmaphorum
APRIL 22, 2024
Discover the innovative use of artificial intelligence (AI) in drug discovery with a focus on GenAI and Large Language Models (LLMs) on Day Two of this informative event. Explore how technology is revolutionising the pharmaceutical industry.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Arvinas gets grant for bifunctional compounds for modulating Tau protein
Pharmaceutical Technology
APRIL 22, 2024
Discover Arvinas Inc's groundbreaking patent for compounds targeting tau protein degradation, offering hope for Alzheimer's and other neurodegenerative diseases. Learn about the promising results and potential therapeutic value of this innovative treatment.
Sanofi's Zantac settlement is worth $100M, or $25K per claimant: Bloomberg
Fierce Pharma
APRIL 22, 2024
Sanofi will pay $100 million—or approximately $25,000 each—to roughly 4,000 claimants who filed lawsuits saying that the French company failed to warn users that its heartburn medicine Zantac (rani | Sanofi will pay approximately $25,000 per person to roughly 4,000 claimants who filed lawsuits saying that the French company failed to warn users that its heartburn medicine Zantac (ranitidine) can cause cancer, Bloomberg reported.
Eurofins Scientific gets grant for method to detect cancer in human individual using cell-free DNA
Pharmaceutical Technology
APRIL 22, 2024
Detect cancer early with Eurofins' patented method analyzing cell-free DNA for methylated CpGs. Personalized treatment options outlined in recent patent.
Soon-Shiong's ImmunityBio bags FDA approval for Anktiva to challenge Merck in bladder cancer
Fierce Pharma
APRIL 22, 2024
After a merger and an FDA rejection, celebrity businessman and biotech entrepreneur Patrick Soon-Shiong’s ImmunityBio has landed the company’s first U.S. | After a merger and an FDA rejection, celebrity businessman and biotech entrepreneur Patrick Soon-Shiong’s ImmunityBio has landed the company’s first U.S. approval in the cancer immunotherapy Anktiva.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content